IMC Chicago’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$800K Buy
44,900
+26,000
+138% +$465K ﹤0.01% 4112
2026
Q1
$338K Buy
18,900
+5,700
+43% +$125K ﹤0.01% 4456
2025
Q4
$356K Buy
+13,200
New +$372K ﹤0.01% 3700

Other funds holding CAI

IMC Chicago's CAI Position: Q2 2026 in Review

IMC Chicago increased its Caris Life Sciences (CAI) stake by 79% in Q2 2026, buying an estimated $183K and bringing the position to 23,148 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #4868.

IMC Chicago first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • IMC Chicago held 23,148 shares of Caris Life Sciences worth $412K as of Q2 2026.
  • IMC Chicago bought 10,229 Caris Life Sciences shares in Q2 2026, an estimated $183K.
  • Caris Life Sciences made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4868 holding.
  • IMC Chicago first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.